Cadrenal Therapeutics Inc (CVKD)

$5.53 +0.11 (2.12%)
Market Cap 12.94M
Revenue (ttm) 0.00
Net Income (ttm) -10.65M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 7,800
Avg Vol 62,968
Day's Range N/A - N/A
Shares Out 2.34M
Stochastic %K 15%
Beta 1.18
Analysts Strong Sell
Price Target $35.67

Company Profile

Cadrenal Therapeutics, Inc. operates as a late-stage biopharmaceutical company focuses on developing therapeutics for rare cardiovascular conditions. The company is developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-...

Industry: Biotechnology
Sector: Healthcare
Phone: 904 300 0701
Address:
822 A1A North, Suite 306, Ponte Vedra, United States
PaidBashar
PaidBashar Feb. 9 at 1:58 PM
$CVKD they found a cure for the money that was building up in your brokerage account
0 · Reply
spyjames
spyjames Feb. 9 at 10:59 AM
$CVKD is a medical diagnostics company; its growth depends on lab adoption and insurance coverage for its tests, a commercial funnel that requires a large, expensive sales force and long sales cycles.
0 · Reply
Jhon05
Jhon05 Feb. 4 at 6:28 PM
$CVKD $1
0 · Reply
Jhon05
Jhon05 Feb. 4 at 5:28 PM
$CVKD Can a company have only four people? If two people argue with their spouses and their mental health deteriorates, the company will collapse
0 · Reply
Jhon05
Jhon05 Feb. 4 at 5:24 PM
$CVKD Don't steal people's hopes.
0 · Reply
Jhon05
Jhon05 Feb. 4 at 5:21 PM
$CVKD go to OTC.
0 · Reply
PaidBashar
PaidBashar Feb. 3 at 8:09 PM
$CVKD I am not a biotech scientist but I play one when I invest
1 · Reply
Jhon05
Jhon05 Feb. 3 at 6:21 PM
$CVKD gambling
0 · Reply
StayPresent
StayPresent Feb. 2 at 5:11 PM
$CVKD garbage
0 · Reply
SavageBeast2
SavageBeast2 Feb. 2 at 5:03 PM
$CVKD What is going on with this stock? It was $20 a year ago.
1 · Reply
Latest News on CVKD
Cadrenal Therapeutics Highlights High Incidence of Thrombotic Complications in Heparin-Induced Thrombocytopenia (HIT) at the J.P. Morgan Healthcare Conference and VLX-1005 as a Potential Therapeutic Solution as the First and Only Selective 12-LOX Inhibitor

Jan 12, 2026, 8:00 AM EST - 4 weeks ago

Cadrenal Therapeutics Highlights High Incidence of Thrombotic Complications in Heparin-Induced Thrombocytopenia (HIT) at the J.P. Morgan Healthcare Conference and VLX-1005 as a Potential Therapeutic Solution as the First and Only Selective 12-LOX Inhibitor

Cadrenal's Pipeline Looks Less Like a Microcap and More Like an Emergency Response System

Dec 30, 2025, 8:00 AM EST - 6 weeks ago

Cadrenal's Pipeline Looks Less Like a Microcap and More Like an Emergency Response System

Cadrenal Is Rebuilding the Parts of Anticoagulation Everyone Else Gave Up On

Dec 29, 2025, 8:00 AM EST - 6 weeks ago

Cadrenal Is Rebuilding the Parts of Anticoagulation Everyone Else Gave Up On

Cadrenal Therapeutics to Conduct Partnering and Investor Meetings During the J.P. Morgan 44th Annual Healthcare Conference in San Francisco on January 12-15, 2026

Dec 17, 2025, 9:00 AM EST - 2 months ago

Cadrenal Therapeutics to Conduct Partnering and Investor Meetings During the J.P. Morgan 44th Annual Healthcare Conference in San Francisco on January 12-15, 2026

Cadrenal's Quiet Expansion Play Is Starting to Get Loud

Dec 12, 2025, 11:00 AM EST - 2 months ago

Cadrenal's Quiet Expansion Play Is Starting to Get Loud

Cadrenal's Anticoagulation Platform Is Expanding in a $40 Billion Market

Dec 12, 2025, 9:45 AM EST - 2 months ago

Cadrenal's Anticoagulation Platform Is Expanding in a $40 Billion Market

Cadrenal Therapeutics Acquires VLX-1005, a First-in-Class Phase 2 12-LOX Inhibitor for Patients with Heparin-Induced Thrombocytopenia (HIT)

Dec 11, 2025, 8:05 AM EST - 2 months ago

Cadrenal Therapeutics Acquires VLX-1005, a First-in-Class Phase 2 12-LOX Inhibitor for Patients with Heparin-Induced Thrombocytopenia (HIT)

Cadrenal Therapeutics Appoints Dr. Lee Golden to Board of Directors

Dec 1, 2025, 9:00 AM EST - 2 months ago

Cadrenal Therapeutics Appoints Dr. Lee Golden to Board of Directors

PTCT

Cadrenal Therapeutics CEO, Quang X. Pham, Receives BioFlorida's Executive of the Year Award

Nov 19, 2025, 8:00 AM EST - 3 months ago

Cadrenal Therapeutics CEO, Quang X. Pham, Receives BioFlorida's Executive of the Year Award

Cadrenal Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Nov 10, 2025, 9:00 AM EST - 3 months ago

Cadrenal Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025

Sep 29, 2025, 4:30 PM EDT - 4 months ago

Cadrenal Therapeutics to Participate in the Lytham Partners Fall 2025 Investor Conference on September 30, 2025

Cadrenal Therapeutics Enhances Anticoagulation Pipeline Through Acquisition of eXIthera's Portfolio of Factor XIa Inhibitors

Sep 15, 2025, 8:00 AM EDT - 5 months ago

Cadrenal Therapeutics Enhances Anticoagulation Pipeline Through Acquisition of eXIthera's Portfolio of Factor XIa Inhibitors

Cadrenal Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Aug 11, 2025, 8:00 AM EDT - 6 months ago

Cadrenal Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Cadrenal Therapeutics Announces Clinical Trial Initiation Plans for Tecarfarin in Patients with End-Stage Kidney Disease (ESKD) Transitioning to Dialysis

Aug 5, 2025, 6:00 AM EDT - 6 months ago

Cadrenal Therapeutics Announces Clinical Trial Initiation Plans for Tecarfarin in Patients with End-Stage Kidney Disease (ESKD) Transitioning to Dialysis

Cadrenal Therapeutics Highlights New Research on Anticoagulation Burden for LVAD Patients

Jun 12, 2025, 8:00 AM EDT - 8 months ago

Cadrenal Therapeutics Highlights New Research on Anticoagulation Burden for LVAD Patients

Cadrenal Therapeutics to Engage Potential Partners at BIO International Convention 2025

Jun 4, 2025, 8:00 AM EDT - 9 months ago

Cadrenal Therapeutics to Engage Potential Partners at BIO International Convention 2025

Cadrenal Therapeutics Announces Tecarfarin Manufacturing Progress in Support of Clinical Trial Readiness

May 15, 2025, 7:30 AM EDT - 9 months ago

Cadrenal Therapeutics Announces Tecarfarin Manufacturing Progress in Support of Clinical Trial Readiness

Cadrenal Therapeutics Reports First-Quarter 2025 Financial Results and Provides Corporate Update

May 8, 2025, 8:00 AM EDT - 10 months ago

Cadrenal Therapeutics Reports First-Quarter 2025 Financial Results and Provides Corporate Update

Cadrenal Therapeutics to Present at Inaugural Centri Capital Conference at Nasdaq

Apr 17, 2025, 9:40 AM EDT - 10 months ago

Cadrenal Therapeutics to Present at Inaugural Centri Capital Conference at Nasdaq

Cadrenal Therapeutics Participates in Key Medical and Business Development Conferences

Apr 3, 2025, 8:00 AM EDT - 11 months ago

Cadrenal Therapeutics Participates in Key Medical and Business Development Conferences

Cadrenal Therapeutics Reports Full Year 2024 Results, Business Highlights, and Path Forward for Clinical Advancement of Tecarfarin

Mar 13, 2025, 4:05 PM EDT - 1 year ago

Cadrenal Therapeutics Reports Full Year 2024 Results, Business Highlights, and Path Forward for Clinical Advancement of Tecarfarin

Cadrenal Therapeutics Announces Collaboration Agreement with Abbott in Support of Pivotal Study of Tecarfarin in Patients with HeartMate 3™ LVAD

Mar 4, 2025, 8:00 AM EST - 1 year ago

Cadrenal Therapeutics Announces Collaboration Agreement with Abbott in Support of Pivotal Study of Tecarfarin in Patients with HeartMate 3™ LVAD

ABT

Cadrenal Therapeutics Announces Chief Medical Officer Transition to Advance Clinical Development of Tecarfarin

Feb 6, 2025, 9:00 AM EST - 1 year ago

Cadrenal Therapeutics Announces Chief Medical Officer Transition to Advance Clinical Development of Tecarfarin

Cadrenal Therapeutics to Present at BIO CEO & Investor Conference

Feb 5, 2025, 9:00 AM EST - 1 year ago

Cadrenal Therapeutics to Present at BIO CEO & Investor Conference

Cadrenal Therapeutics to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

Jan 9, 2025, 8:44 AM EST - 1 year ago

Cadrenal Therapeutics to Participate in the Lytham Partners 2025 Investor Healthcare Summit on January 13, 2025

Cadrenal Therapeutics Provides 2024 Year-End Company Update, Reinforcing Clinical Development Plan for Tecarfarin in LVAD and Other Rare Cardiovascular Indications

Dec 31, 2024, 8:00 AM EST - 1 year ago

Cadrenal Therapeutics Provides 2024 Year-End Company Update, Reinforcing Clinical Development Plan for Tecarfarin in LVAD and Other Rare Cardiovascular Indications

Cadrenal Therapeutics Gears Up for the 43rd Annual J.P. Morgan Healthcare Conference Week with Event Participation and Investor/Partner Meetings

Dec 18, 2024, 9:00 AM EST - 1 year ago

Cadrenal Therapeutics Gears Up for the 43rd Annual J.P. Morgan Healthcare Conference Week with Event Participation and Investor/Partner Meetings

Cadrenal Therapeutics Named Anticoagulation Therapy Company of the Year by Pharma Tech Outlook

Nov 19, 2024, 9:00 AM EST - 1 year ago

Cadrenal Therapeutics Named Anticoagulation Therapy Company of the Year by Pharma Tech Outlook

CADRENAL THERAPEUTICS HIGHLIGHTS PRESENTATION AT EUROPEAN ASSOCIATION FOR CARDIO-THORACIC SURGERY (EACTS) MEDICAL CONGRESS

Nov 12, 2024, 9:00 AM EST - 1 year ago

CADRENAL THERAPEUTICS HIGHLIGHTS PRESENTATION AT EUROPEAN ASSOCIATION FOR CARDIO-THORACIC SURGERY (EACTS) MEDICAL CONGRESS

CADRENAL THERAPEUTICS PROVIDES THIRD-QUARTER CORPORATE UPDATE

Nov 7, 2024, 9:00 AM EST - 1 year ago

CADRENAL THERAPEUTICS PROVIDES THIRD-QUARTER CORPORATE UPDATE

Cadrenal Therapeutics Announces Exercise of Warrants for $4.7 Million Gross Proceeds

Nov 1, 2024, 8:00 PM EDT - 1 year ago

Cadrenal Therapeutics Announces Exercise of Warrants for $4.7 Million Gross Proceeds

Cadrenal Therapeutics Raises $5.1 Million via At-The-Market Facility

Oct 24, 2024, 9:00 AM EDT - 1 year ago

Cadrenal Therapeutics Raises $5.1 Million via At-The-Market Facility

CADRENAL THERAPEUTICS JOINS CORPORATE COUNCIL OF ANTICOAGULATION FORUM

Oct 23, 2024, 9:00 AM EDT - 1 year ago

CADRENAL THERAPEUTICS JOINS CORPORATE COUNCIL OF ANTICOAGULATION FORUM

Cadrenal Therapeutics to Participate in Lytham Partners Fall 2024 Investor Conference

Sep 23, 2024, 4:15 PM EDT - 1 year ago

Cadrenal Therapeutics to Participate in Lytham Partners Fall 2024 Investor Conference

Cadrenal Therapeutics Announces Upcoming Type-B FDA Meeting in September to Discuss Tecarfarin Trial in LVAD Patients

Aug 22, 2024, 9:00 AM EDT - 1 year ago

Cadrenal Therapeutics Announces Upcoming Type-B FDA Meeting in September to Discuss Tecarfarin Trial in LVAD Patients

Published Findings Highlight Tecarfarin's Potential and Reinforce Need for Better Anticoagulation Therapy in LVAD Patients

Aug 20, 2024, 9:00 AM EDT - 1 year ago

Published Findings Highlight Tecarfarin's Potential and Reinforce Need for Better Anticoagulation Therapy in LVAD Patients

Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now

Aug 20, 2024, 7:00 AM EDT - 1 year ago

Presenting on the Emerging Growth Conference 74 Day 1 on August 21 Register Now

CIA ELUT EUDA GDTC GOSS GOVX IMRN

Cadrenal Therapeutics to Present at Upcoming Investor Conferences

Aug 14, 2024, 9:00 AM EDT - 1 year ago

Cadrenal Therapeutics to Present at Upcoming Investor Conferences

Cadrenal Therapeutics Provides Second Quarter 2024 Corporate Update

Aug 7, 2024, 4:05 PM EDT - 1 year ago

Cadrenal Therapeutics Provides Second Quarter 2024 Corporate Update

Cadrenal Therapeutics and Abbott Initiate Collaborative Effort to Advance Novel Anticoagulant Tecarfarin for Patients with LVADs

Aug 6, 2024, 9:00 AM EDT - 1 year ago

Cadrenal Therapeutics and Abbott Initiate Collaborative Effort to Advance Novel Anticoagulant Tecarfarin for Patients with LVADs

ABT

Cadrenal Therapeutics to Present at the Emerging Growth Conference on July 18, 2024

Jul 17, 2024, 9:00 AM EDT - 1 year ago

Cadrenal Therapeutics to Present at the Emerging Growth Conference on July 18, 2024

Cadrenal Therapeutics to Present at the Emerging Growth Conference on June 12, 2024

Jun 11, 2024, 4:15 PM EDT - 1 year ago

Cadrenal Therapeutics to Present at the Emerging Growth Conference on June 12, 2024

Cadrenal Therapeutics Highlights Presentation of New Trial Data at ISHLT Conference Demonstrating the Importance of Anticoagulation Quality in LVAD Patients

Jun 3, 2024, 9:00 AM EDT - 1 year ago

Cadrenal Therapeutics Highlights Presentation of New Trial Data at ISHLT Conference Demonstrating the Importance of Anticoagulation Quality in LVAD Patients

ABT

Cadrenal Therapeutics to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024

May 23, 2024, 9:00 AM EDT - 1 year ago

Cadrenal Therapeutics to Participate in the Lytham Partners Spring 2024 Investor Conference on May 30, 2024

Cadrenal Therapeutics Provides First Quarter 2024 Corporate Update

May 9, 2024, 9:00 AM EDT - 1 year ago

Cadrenal Therapeutics Provides First Quarter 2024 Corporate Update

Cadrenal Therapeutics to Participate in Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference on April 18, 2024

Apr 11, 2024, 4:30 PM EDT - 2 years ago

Cadrenal Therapeutics to Participate in Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference on April 18, 2024

Cadrenal Therapeutics Receives FDA Orphan Drug Designation for Tecarfarin for Prevention of Thromboembolism and Thrombosis in Patients with LVADs, RVADs, Biventricular Assist Devices, and Total Artificial Hearts

Apr 9, 2024, 9:00 AM EDT - 2 years ago

Cadrenal Therapeutics Receives FDA Orphan Drug Designation for Tecarfarin for Prevention of Thromboembolism and Thrombosis in Patients with LVADs, RVADs, Biventricular Assist Devices, and Total Artificial Hearts

Cadrenal Therapeutics Provides Fourth Quarter 2023 Corporate Update

Mar 11, 2024, 9:00 AM EDT - 2 years ago

Cadrenal Therapeutics Provides Fourth Quarter 2023 Corporate Update

Cadrenal Therapeutics to Participate at Technology and Heart Failure Therapeutics (THT) Conference

Feb 26, 2024, 9:00 AM EST - 2 years ago

Cadrenal Therapeutics to Participate at Technology and Heart Failure Therapeutics (THT) Conference

Cadrenal Therapeutics Appoints Jeff Cole as Chief Operating Officer in Advance of Tecarfarin Phase 3 Pivotal Trial

Feb 8, 2024, 9:00 AM EST - 2 years ago

Cadrenal Therapeutics Appoints Jeff Cole as Chief Operating Officer in Advance of Tecarfarin Phase 3 Pivotal Trial

PaidBashar
PaidBashar Feb. 9 at 1:58 PM
$CVKD they found a cure for the money that was building up in your brokerage account
0 · Reply
spyjames
spyjames Feb. 9 at 10:59 AM
$CVKD is a medical diagnostics company; its growth depends on lab adoption and insurance coverage for its tests, a commercial funnel that requires a large, expensive sales force and long sales cycles.
0 · Reply
Jhon05
Jhon05 Feb. 4 at 6:28 PM
$CVKD $1
0 · Reply
Jhon05
Jhon05 Feb. 4 at 5:28 PM
$CVKD Can a company have only four people? If two people argue with their spouses and their mental health deteriorates, the company will collapse
0 · Reply
Jhon05
Jhon05 Feb. 4 at 5:24 PM
$CVKD Don't steal people's hopes.
0 · Reply
Jhon05
Jhon05 Feb. 4 at 5:21 PM
$CVKD go to OTC.
0 · Reply
PaidBashar
PaidBashar Feb. 3 at 8:09 PM
$CVKD I am not a biotech scientist but I play one when I invest
1 · Reply
Jhon05
Jhon05 Feb. 3 at 6:21 PM
$CVKD gambling
0 · Reply
StayPresent
StayPresent Feb. 2 at 5:11 PM
$CVKD garbage
0 · Reply
SavageBeast2
SavageBeast2 Feb. 2 at 5:03 PM
$CVKD What is going on with this stock? It was $20 a year ago.
1 · Reply
Stock_Boomer
Stock_Boomer Feb. 1 at 7:39 PM
$CVKD due for squeeze play
0 · Reply
StayPresent
StayPresent Jan. 30 at 6:47 PM
$CVKD is a scam pos
0 · Reply
Jhon05
Jhon05 Jan. 29 at 1:26 PM
$CVKD They are playing with the investors.
0 · Reply
StayPresent
StayPresent Jan. 29 at 12:37 PM
$CVKD scam
0 · Reply
StayPresent
StayPresent Jan. 29 at 11:29 AM
$CVKD trying to pump this scam pos is a joke.
0 · Reply
StayPresent
StayPresent Jan. 28 at 10:09 PM
$CVKD scam
0 · Reply
StayPresent
StayPresent Jan. 28 at 1:18 AM
$CVKD scam
0 · Reply
WallStreetBuyDip
WallStreetBuyDip Jan. 27 at 4:09 AM
Comparing trending tickers $AGQ vs $CVKD: AGQ has climbed 9.70% to $350.89 with a substantial increase in trading volume, hitting 24.3M shares, which is over 8 times its average volume. CVKD also saw gains, up 6.06% to $7.70, on a trading volume of 98.1K, nearly 3 times its usual activity. While both stocks are experiencing significant upticks in volume and price, AGQ's larger relative increase in both price and trading volume suggests it's capturing more market attention compared to CVKD.
0 · Reply